Evidence-Based Answers

Evidence Central™ is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research.


Evidence Central for Mobile Devices

Evidence Central iOS iPhone iPad Android

Evidence Central from Unbound Medicine, available for iOS® and Android™, is optimized for each platform and features superior navigation, so answers are easy to find at the bedside or anywhere they’re needed. Learn More

Word of the Day

Oseltamivir slightly decreases flu symptom duration but not hospitalizations

Clinical Question:
Is oseltamivir effective in reducing symptom duration and complications in children and adults with presumed influenza?

Bottom Line:
Treatment of children with oseltamivir (Tamiflu) will decrease symptom duration by approximately 1 day but will not reduce hospitalizations and does not seem to be effective in children with asthma. In adults, symptom reduction is less striking (less than 1 day) and hospitalization will not be decreased. Vomiting in both groups is more likely with treatment. (LOE = 1a)

Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014;348:g2545.  [PMID:24811411]

Study Design:
Meta-analysis (randomized controlled trials)


Various (meta-analysis)

The authors performing this systematic review of the literature launched a 4-year campaign to obtain unpublished data from the manufacturer to supplement the results of a literature review they previously performed for a Cochrane Review. They included 23 reports that evaluated the use of oseltamivir in children or adults for treatment, prophylaxis, and postexposure prophylaxis of influenza. Three authors independently abstracted and compared the study results. They included 20 studies of moderate quality; up to half the studies had problems with randomization, allocation concealment, and masking of participants, as well as issues with adequate recruiting of patients and reporting of outcomes. For treatment of adults, oseltamivir reduced the time to first alleviation of symptoms from 7 days to 6.3 days. Hospitalization rates were not different. Nausea and vomiting are increased with treatment (number needed to treat to harm [NNTH] = 28 and 22, respectively). In children, the results were more striking: an average shortening of symptoms by 29 hours, with wide variability (95% CI, 12 - 47 hours). There was no difference in outcomes for children with asthma. Hospitalization of children was not reduced with treatment. The likelihood of vomiting is higher with treatment (NNTH = 19). A single study showed a reduction in influenza when used for prophylaxis. These results are similar to those from another meta-analysis published last year (Fam Pract 2013;30(2):125-133).


Site Licenses

Site license

Site Licenses are available for schools, universities, hospitals, government agencies, and companies. For more information, contact us.